Gala Beykin, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Beykin’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$14,455
Medicare paid this office $14,455 for 98 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit | 42 | $1,993 | $30 |
| Short return visit (20+ min) | 30 | $1,686 | $56 |
| New patient visit (30+ min) | 23 | $1,539 | $67 |
| Exam of visual field with extended testing | 41 | $1,286 | $24 |
| Imaging of optic nerve | 54 | $1,113 | $18 |
See all 6 services
| Short return visit | 42 | $1,993 | $30 |
| Short return visit (20+ min) | 30 | $1,686 | $56 |
| New patient visit (30+ min) | 23 | $1,539 | $67 |
| Exam of visual field with extended testing | 41 | $1,286 | $24 |
| Imaging of optic nerve | 54 | $1,113 | $18 |
| Imaging of retina | 23 | $463 | $20 |
Procedures Medicare counted
| Cataract surgery | 23 | More than 47% of doctors who do this |
Who their Medicare patients are
98 Original Medicare patients in 2024. Average age 74 · Women 57% · Also on Medicaid 24% · Health risk score 0.98. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 49% · Diabetes 29% · Chronic kidney disease 16% · Coronary heart disease 15% · Atrial fibrillation 14% · Cancer 13% · Depression 13% · Heart failure 12%.
The office billed $89,445, Medicare allowed $19,869 and paid $14,455; for 288 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 98 | 288 | 74 | 0.98 | $89,445 | $14,455 |
| 2023 | 59 | 123 | 76 | 0.98 | $38,151 | $6,465 |
| 2022 | 44 | 76 | 76 | 1.84 | $33,439 | $3,229 |
| 2021 | 66 | 92 | 75 | 1.43 | $46,775 | $5,564 |
| 2020 | 26 | 44 | 75 | 1.27 | $16,394 | $3,533 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| New patient visit (45+ min) | 13 | $1,596 | $123 |
| Short return visit | 23 | $1,060 | $31 |
| Imaging of retina | 22 | $573 | $22 |
| Imaging of optic nerve | 15 | $287 | $19 |
2022: 2 services
| Short return visit | 24 | $1,046 | $30 |
| Imaging of retina | 13 | $308 | $24 |
2021: 3 services
| Short return visit (20+ min) | 17 | $766 | $43 |
| Imaging of retina | 13 | $413 | $24 |
| Short return visit | 11 | $395 | $30 |
Medicaid work
$876 in 2023
Medicaid paid $876 for 14 billed services this clinician did in 2023, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (45+ min) | 14 | $876 |
| 2023 | 14 | 1 | 14 | $876 |
Drugs they prescribed that Part D paid
$37,241
Pharmacies billed $37,241 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 314) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
167 generic and 147 brand-name prescriptions · $37,241 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lumigan | 27 | $10,174 | $377 |
| Rhopressa | 14 | $6,255 | $447 |
| Brimonidine | 30 | $2,551 | $85 |
| Latanoprost | 99 | $1,095 | $11 |
| Prednisolone Acetate | 18 | $798 | $44 |
See all 10 drugs
| Lumigan | 27 | $10,174 | $377 |
| Rhopressa | 14 | $6,255 | $447 |
| Brimonidine | 30 | $2,551 | $85 |
| Latanoprost | 99 | $1,095 | $11 |
| Prednisolone Acetate | 18 | $798 | $44 |
| Ketorolac Tromethamine | 15 | $310 | $21 |
| Dorzolamide-Timolol | 22 | $283 | $13 |
| Dorzolamide | 11 | $269 | $24 |
| Moxifloxacin | 13 | $184 | $14 |
| Timolol Maleate | 12 | $146 | $12 |
Year by year
| 2024 | 314 | 100 | 0% (0) | 47% | $37,241 |
| 2023 | 904 | 306 | 0% (0) | 52% | $185,108 |
| 2022 | 1,367 | 386 | 0% (0) | 50% | $235,428 |
| 2021 | 755 | 290 | 0% (0) | 55% | $125,482 |
| 2020 | 112 | 48 | 0% (0) | 62% | $14,314 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Rhopressa | 45 | $19,759 | $439 |
| Lumigan | 33 | $17,841 | $541 |
| Alphagan P | 28 | $16,746 | $598 |
| Restasis | 16 | $16,174 | $1,011 |
| Rocklatan | 32 | $13,009 | $407 |
| Simbrinza | 22 | $11,100 | $505 |
| Vyzulta | 15 | $9,734 | $649 |
| Brinzolamide | 26 | $7,838 | $301 |
| Combigan | 15 | $7,112 | $474 |
| Travoprost | 28 | $5,840 | $209 |
| Latanoprost | 262 | $4,363 | $17 |
| Timolol Maleate | 11 | $4,352 | $396 |
| Tafluprost | 19 | $3,968 | $209 |
| Dorzolamide-Timolol | 14 | $3,719 | $266 |
| Brimonidine | 62 | $3,642 | $59 |
| Dorzolamide-Timolol | 57 | $2,243 | $39 |
| Dorzolamide | 40 | $1,061 | $27 |
| Prednisolone Acetate | 19 | $1,055 | $56 |
| Timolol Maleate | 49 | $689 | $14 |
| Ketorolac Tromethamine | 13 | $456 | $35 |
| Moxifloxacin | 14 | $342 | $24 |
2022: 19 drugs
| Restasis | 34 | $28,600 | $841 |
| Rhopressa | 45 | $23,475 | $522 |
| Lumigan | 44 | $22,601 | $514 |
| Travoprost | 74 | $17,438 | $236 |
| Alphagan P | 41 | $15,817 | $386 |
| Combigan | 31 | $14,637 | $472 |
| Zioptan | 26 | $11,050 | $425 |
| Azopt | 30 | $10,718 | $357 |
| Latanoprost | 439 | $8,265 | $19 |
| Simbrinza | 30 | $7,793 | $260 |
| Brinzolamide | 18 | $7,704 | $428 |
| Brimonidine | 103 | $7,205 | $70 |
| Brimonidine Tartrate-Timolol | 14 | $6,089 | $435 |
| Travatan Z | 12 | $4,785 | $399 |
| Dorzolamide-Timolol | 94 | $3,683 | $39 |
| Dorzolamide-Timolol | 24 | $2,606 | $109 |
| Timolol Maleate | 109 | $1,834 | $17 |
| Dorzolamide | 54 | $1,592 | $29 |
| Prednisolone Acetate | 16 | $930 | $58 |
2021: 18 drugs
| Restasis | 34 | $22,769 | $670 |
| Rhopressa | 35 | $16,468 | $471 |
| Lumigan | 20 | $8,770 | $438 |
| Azopt | 20 | $8,700 | $435 |
| Alphagan P | 14 | $6,873 | $491 |
| Travoprost | 30 | $6,182 | $206 |
| Latanoprost | 206 | $5,010 | $24 |
| Simbrinza | 19 | $4,563 | $240 |
| Travatan Z | 11 | $4,082 | $371 |
| Brimonidine | 37 | $3,737 | $101 |
| Vyzulta | 12 | $2,911 | $243 |
| Dorzolamide-Timolol | 48 | $2,440 | $51 |
| Prednisolone Acetate | 33 | $1,965 | $60 |
| Dorzolamide | 23 | $1,445 | $63 |
| Ketorolac Tromethamine | 26 | $987 | $38 |
| Timolol Maleate | 55 | $852 | $15 |
| Moxifloxacin | 15 | $445 | $30 |
| Erythromycin | 28 | $357 | $13 |
2020: 4 drugs
| Prednisolone Acetate | 14 | $913 | $65 |
| Ketorolac Tromethamine | 15 | $528 | $35 |
| Moxifloxacin | 15 | $448 | $30 |
| Latanoprost | 15 | $358 | $24 |
Money from drug and device companies
$92 in 2025
| 2025 | 2 | 2 | None | $92 |
| 2024 | 3 | 4 | None | $244 |
| 2022 | 1 | 1 | None | $43 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Hydrus Microstent | $52 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $40 | 1 payment
|
See all 2 published payments
| Bausch & Lomb Americas | Meals · 2025-11-18 | Vyzulta | $40 |
| Alcon Vision | Meals · 2025-09-17 | Hydrus Microstent | $52 |
See earlier years (2024, 2022)
2024: $244
| Glaukos | Istent Trabecular Micro-Bypass System Model Is3 | $176 | 2 payments
|
| Alcon Vision | Hydrus Microstent | $43 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Simplicity | $24 | 1 payment
|
2022: $43
| Johnson & Johnson Surgical Vision | Tecnis Iol | $43 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1467084764
- Licence
- CA SPI641
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0009X (207WX0009X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2020-02-05
- NPI last updated
- 2024-03-18
- NPI record certified
- 2024-03-18
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2452 Watson Ct, Palo Alto, CA, 94303